NCT04122911View on ClinicalTrials.gov

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 29, 2017

Primary Completion Date

December 30, 2017

Study Completion Date

December 16, 2019

Conditions
Neuroendocrine Carcinomas
Interventions
DRUG

Temozolomide

pharmacological

Trial Locations (1)

80131

Istituto Tumori di Napoli - Fondazione G. Pascale, Napoli

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER

NCT04122911 - Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas | Biotech Hunter | Biotech Hunter